Research reveals potential target for enfortumab vedotin therapy in urothelial carcin

[News]

Under the leadership of PD Dr. Niklas Kl?mper, Assistant Physician at the Department of Urology at the University Hospital Bonn (UKB) and Clinician Scientist of the BMBF-funded ACCENT program and PD Dr. Markus Eckstein, senior physician at the Institute of Pathology at the Uniklinikum Erlangen of the Friedrich-Alexander-University Erlangen-N?rnberg (FAU), an interdisciplinary research team has published new findings that indicate which patients with advanced urothelial carcinoma could benefit in particular from the new targeted therapy with the antibody-drug conjugate enfortumab vedotin.

More... (https://www.news-medical.net/news/20240424/Research-reveals-potential-target-for-enfortumab-vedotin-therapy-in-urothelial-carcinoma.aspx)